US-based biopharmaceutical firm Zavante Therapeutics has randomised the first patient in the Zeus pivotal clinical study of ZTI-01 (fosfomycin for injection) to treat complicated urinary tract infections (cUTI), including acute pyelonephritis.

ZTI-01 is the company’s investigational broad spectrum IV antibiotic being developed to treat infections, as well as those caused by multidrug resistant pathogens.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

ZEUS is a multi-centre, randomised, double-blind and comparative study designed to evaluate the safety and efficacy of ZTI-01 when compared with piperacillin / tazobactam, to treat hospitalised adults afflicted with cUTI including acute pyelonephritis.

The study commenced in April this year and is expected to involve approximately 460 hospitalised patients.

"We anticipate filing a New Drug Application, or NDA, for ZTI-01 with the US Food and Drug Administration late in the second half of 2017."

Zavante founder, president and CEO Ted Schroeder said: "Randomisation of our first patient in the ZEUS study is an important clinical milestone for Zavante.

"We anticipate filing a New Drug Application, or NDA, for ZTI-01 with the US Food and Drug Administration late in the second half of 2017.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are excited to introduce ZTI-01 as a new class of injectable antibiotics that we hope will be a valuable tool for physicians in the US fighting serious infections, including those caused by multidrug-resistant (MDR) pathogens in the hospital setting."

ZTI-01 has exhibited a wide range of bactericidal Gram-negative and Gram-positive activity, as well as being active against the contemporary MDR bacterial strains and thereby addressing the limited antibiotic therapeutic choice against infections.